Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by UBS Group

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a report released on Wednesday, Zacks reports.

Several other analysts have also issued reports on the company. HC Wainwright reissued a “buy” rating and set a $455.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, September 21st. Barclays dropped their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Finally, Raymond James Financial upgraded shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective on the stock in a research note on Monday, August 3rd. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $364.95.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $2.20 during trading on Wednesday, hitting $231.83. The company had a trading volume of 1,404,802 shares, compared to its average volume of 1,301,571. The firm has a market capitalization of $31.02 billion, a P/E ratio of 43.09 and a beta of 0.28. Alnylam Pharmaceuticals has a one year low of $197.81 and a one year high of $495.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock’s 50-day moving average price is $239.35 and its 200 day moving average price is $274.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company’s revenue was up 66.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.51) EPS. Equities analysts expect that Alnylam Pharmaceuticals will post 6.68 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of ALNY. TD Waterhouse Canada Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 26.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 2,304 shares of the biopharmaceutical company’s stock valued at $532,000 after purchasing an additional 479 shares during the last quarter. TB Alternative Assets Ltd. acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $1,076,000. Assenagon Asset Management S.A. increased its position in Alnylam Pharmaceuticals by 8.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 168,320 shares of the biopharmaceutical company’s stock worth $41,531,000 after purchasing an additional 12,625 shares in the last quarter. Fortitude Family Office LLC lifted its stake in Alnylam Pharmaceuticals by 10.5% in the 3rd quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 55 shares during the last quarter. Finally, Sanders Morris Harris LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $777,000. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.